PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

16 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

14 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

14 Aug 2023 06:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

07 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

02 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

17 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

11 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

20 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

14 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

05 Jun 2023 13:52:38 By Nasdaq GlobeNewswire

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

25 May 2023 16:00:00 By Nasdaq GlobeNewswire

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

18 May 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

15 May 2023 06:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

24 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

03 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

30 Mar 2023 07:00:00 By Nasdaq GlobeNewswire